As of 2024-12-14, the EV/EBITDA ratio of Beam Therapeutics Inc (BEAM) is -13.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BEAM's latest enterprise value is 2,082.68 mil USD. BEAM's TTM EBITDA according to its financial statements is -157.40 mil USD. Dividing these 2 quantities gives us the above BEAM EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 15.1x | 13.8x |
| Forward P/E multiples | 15.2x - 21.1x | 15.5x |
| Fair Price | (21.85) - 3,210.72 | 1,165.71 |
| Upside | -178.2% - 11395.6% | 4073.7% |
| Date | EV/EBITDA |
| 2024-12-13 | -13.23 |
| 2024-12-12 | -13.30 |
| 2024-12-11 | -13.74 |
| 2024-12-10 | -14.43 |
| 2024-12-09 | -13.01 |
| 2024-12-06 | -12.59 |
| 2024-12-05 | -11.86 |
| 2024-12-04 | -12.23 |
| 2024-12-03 | -12.21 |
| 2024-12-02 | -13.42 |
| 2024-11-29 | -12.94 |
| 2024-11-27 | -12.85 |
| 2024-11-26 | -12.13 |
| 2024-11-25 | -12.56 |
| 2024-11-22 | -11.72 |
| 2024-11-21 | -10.94 |
| 2024-11-20 | -11.42 |
| 2024-11-19 | -11.84 |
| 2024-11-18 | -11.23 |
| 2024-11-15 | -11.19 |
| 2024-11-14 | -12.38 |
| 2024-11-13 | -13.01 |
| 2024-11-12 | -13.24 |
| 2024-11-11 | -14.51 |
| 2024-11-08 | -12.77 |
| 2024-11-07 | -12.27 |
| 2024-11-06 | -12.54 |
| 2024-11-05 | -11.13 |
| 2024-11-04 | -11.35 |
| 2024-11-01 | -10.60 |
| 2024-10-31 | -10.06 |
| 2024-10-30 | -10.38 |
| 2024-10-29 | -10.20 |
| 2024-10-28 | -10.30 |
| 2024-10-25 | -9.88 |
| 2024-10-24 | -10.16 |
| 2024-10-23 | -10.02 |
| 2024-10-22 | -10.50 |
| 2024-10-21 | -10.72 |
| 2024-10-18 | -10.98 |
| 2024-10-17 | -11.35 |
| 2024-10-16 | -12.58 |
| 2024-10-15 | -12.40 |
| 2024-10-14 | -12.53 |
| 2024-10-11 | -11.54 |
| 2024-10-10 | -10.65 |
| 2024-10-09 | -10.87 |
| 2024-10-08 | -10.78 |
| 2024-10-07 | -10.84 |
| 2024-10-04 | -10.85 |